Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
7. Mako gets a little Wall Street love
Mako Surgical Corp.’s (NSDQ:MAKO) commercial launch of the RIO surgical robotic arm for hip replacement surgery won some love from analysts and investors on Wall Street today.
6. BSX escapes fraud case
A federal judge in Massachusetts tossed a shareholders’ lawsuit accusing Boston Scientific Corp. (NYSE:BSX) of fraudulently concealing problems within its cardiac rhythm management division that prompted it to fire several members of its CRM sales force.
Sign up to get our free newsletters delivered right to your inbox.
5. Medtronic wins big in NuVasive spat
Medtronic scored a big win yesterday in its patent war with NuVasive Inc., after a California jury awards it $101.2 million in damages over spinal implant technology; NuVasive, which won a $660,000 award for Medtronic’s infringement of one of its patents, vows to fight the decision.
4. Advanced Cell Technology launches historical embryonic stem cell trial
Advanced Cell Technology Inc. (OTC:ACTC) is set to begin Europe’s first study involving human embryonic stem cells, as it begins a trial to consider an experimental treatment for a form of juvenile blindness.
3. MDT weathers a storm of Infuse lawsuits
Personal injury lawsuits over its controversial Infuse bone-growth protein are beginning to pile up for Medtronic Inc. (NYSE:MDT) and a Minnesota judge ordered the medical device colossus to turn over safety data.
2. Bard makes a bid for catheter maker Clearstream
C.R. Bard (NYSE:BCR) announced a $68.5 million deal in place to acquire Clearstream Technologies, an Ireland-based developer of catheters used in angioplasty procedures.
1. Mahoney: Boston Scientific’s new man in charge
The terms of Michael Mahoney’s move from Johnson and Johnson (NYSE:JNJ) to well-paid president – and eventual CEO – at its Natick, Mass.-based rival, Boston Scientific (NYSE:BSX), were driven by a strict non-competition agreement between J&J and Mahoney.